322 related articles for article (PubMed ID: 19952991)
21. Influence of preoperative intravitreal bevacizumab on visual function in eyes with proliferative diabetic retinopathy.
Ushida H; Kachi S; Asami T; Ishikawa K; Kondo M; Terasaki H
Ophthalmic Res; 2013; 49(1):30-6. PubMed ID: 23038607
[TBL] [Abstract][Full Text] [Related]
22. Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy.
Yang CM; Yeh PT; Yang CH; Chen MS
Am J Ophthalmol; 2008 Aug; 146(2):211-217. PubMed ID: 18547539
[TBL] [Abstract][Full Text] [Related]
23. [Intravitreal bevacizumab pretreatment in vitrectomy for severe diabetic retinopathy: a series of six cases].
Couzinet A; Auriol S; Lequeux L; Arné JL; Pagot-Mathis V
J Fr Ophtalmol; 2012 Apr; 35(4):260-5. PubMed ID: 21889820
[TBL] [Abstract][Full Text] [Related]
24. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
[TBL] [Abstract][Full Text] [Related]
25. The relation between bevacizumab injection and the formation of subretinal fibrosis in diabetic patients with panretinal photocoagulation.
Batman C; Ozdamar Y
Ophthalmic Surg Lasers Imaging; 2010; 41(2):190-5. PubMed ID: 20307036
[TBL] [Abstract][Full Text] [Related]
26. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
27. Bevacizumab (Avastin) as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series.
Abdelhakim MA; Macky TA; Mansour KA; Mortada HA
Ophthalmic Res; 2011; 45(1):23-30. PubMed ID: 20714187
[TBL] [Abstract][Full Text] [Related]
28. Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy.
Minnella AM; Savastano CM; Ziccardi L; Scupola A; Falsini B; Balestrazzi E
Acta Ophthalmol; 2008 Sep; 86(6):683-7. PubMed ID: 17995986
[TBL] [Abstract][Full Text] [Related]
29. Effects of intravitreally injected bevacizumab on vascular endothelial growth factor in fellow eyes.
Matsuyama K; Ogata N; Matsuoka M; Wada M; Nishimura T; Takahashi K
J Ocul Pharmacol Ther; 2011 Aug; 27(4):379-83. PubMed ID: 21810018
[TBL] [Abstract][Full Text] [Related]
30. The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy.
Ahn J; Woo SJ; Chung H; Park KH
Ophthalmology; 2011 Nov; 118(11):2218-26. PubMed ID: 21724263
[TBL] [Abstract][Full Text] [Related]
31. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy.
Yeh PT; Yang CM; Lin YC; Chen MS; Yang CH
Retina; 2009 Jun; 29(6):768-74. PubMed ID: 19516117
[TBL] [Abstract][Full Text] [Related]
32. Preoperative Timing of Intravitreal Bevacizumab Injection for Proliferative Diabetic Retinopathy Patients.
Feng J; Li B; Wen J; Jiang Y
Ophthalmic Res; 2018; 60(4):250-257. PubMed ID: 30380554
[TBL] [Abstract][Full Text] [Related]
33. Reducing the incidence of early postoperative vitreous haemorrhage by preoperative intravitreal bevacizumab in vitrectomy for diabetic tractional retinal detachment.
Yeung L; Liu L; Wu WC; Kuo YH; Chao AN; Chen KJ; Yang KJ; Chen TL; Lai CC
Acta Ophthalmol; 2010 Sep; 88(6):635-40. PubMed ID: 19432872
[TBL] [Abstract][Full Text] [Related]
34. Role of intravitreal bevacizumab (Avastin) injected at the end of diabetic vitrectomy in preventing postoperative recurrent vitreous hemorrhage.
Cheema RA; Mushtaq J; Al-Khars W; Al-Askar E; Cheema MA
Retina; 2010; 30(10):1646-50. PubMed ID: 20634777
[TBL] [Abstract][Full Text] [Related]
35. Expression of vascular endothelial growth factor and intravitreal anti-VEGF therapy with bevacizumab in vasoproliferative retinal tumors.
Saito W; Kase S; Fujiya A; Dong Z; Noda K; Ishida S
Retina; 2013 Oct; 33(9):1959-67. PubMed ID: 23652580
[TBL] [Abstract][Full Text] [Related]
36. Intravitreal anti-VEGF therapy blocks inflammatory cell infiltration and re-entry into the circulation in retinal angiogenesis.
Nakao S; Arima M; Ishikawa K; Kohno R; Kawahara S; Miyazaki M; Yoshida S; Enaida H; Hafezi-Moghadam A; Kono T; Ishibashi T
Invest Ophthalmol Vis Sci; 2012 Jun; 53(7):4323-8. PubMed ID: 22661475
[TBL] [Abstract][Full Text] [Related]
37. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy.
Mason JO; Nixon PA; White MF
Am J Ophthalmol; 2006 Oct; 142(4):685-8. PubMed ID: 17011869
[TBL] [Abstract][Full Text] [Related]
38. Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity.
Kychenthal A; Dorta P
Retina; 2010 Apr; 30(4 Suppl):S32-6. PubMed ID: 20224474
[TBL] [Abstract][Full Text] [Related]
39. Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage.
Huang YH; Yeh PT; Chen MS; Yang CH; Yang CM
Retina; 2009 Sep; 29(8):1134-40. PubMed ID: 19672218
[TBL] [Abstract][Full Text] [Related]
40. Effects of intravitreal injection of bevacizumab on inflammatory cytokines in the vitreous with proliferative diabetic retinopathy.
Suzuki Y; Suzuki K; Yokoi Y; Miyagawa Y; Metoki T; Nakazawa M
Retina; 2014 Jan; 34(1):165-71. PubMed ID: 23851630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]